CoAxia Inc.
This article was originally published in Start Up
Executive Summary
CoAxia Inc. has a new approach to neuroprotection for ischemic stroke: by partially restricting blood flow in the lower body, it diverts a larger portion of cardiac output into the cerebral vasculature to perfuse the penumbra, keeping those cells viable until circulation is restored. CoAxia believes its technology is simple, safe, and will dramatically expand the treatment window for ischemic stroke patients.
You may also be interested in...
BeneChill Inc.
Lowering brain temperature protects cerebral tissue from ischemic damage, but any delay in inducing hypothermia compromises patient outcomes. BeneChill Inc. noninvasively delivers PFCs to the nose, and the resulting rapid heat exchange selectively cools the brain. The company will design a device for in-hospital use, as well as a version that can be used by first responders in the field.
BeneChill Inc.
Lowering brain temperature protects cerebral tissue from ischemic damage, but any delay in inducing hypothermia compromises patient outcomes. BeneChill Inc. noninvasively delivers PFCs to the nose, and the resulting rapid heat exchange selectively cools the brain. The company will design a device for in-hospital use, as well as a version that can be used by first responders in the field.
Persistently Seeking Stroke Solutions
Even as ischemic stroke researchers debate what went wrong following a string of high-profile, expensive clinical trial failures, they're optimistic that advances in understanding of the disease and application of lessons learned from past mistakes will yield more effective therapies.